Sirben

Quick links to important sections

Sirben

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sirben

Sirben is a medicinal product containing the active ingredient Mebendazole, which is formally classified as an anthelmintic drug used to manage helminthiasis, commonly known as parasitic worm infections.


Quick Facts About Sirben (Mebendazole)

Property Description
Active Ingredient Mebendazole (INN)
Form Tablet, Oral suspension
Pharmacological Class Anthelmintic drug
Common Use Elimination of intestinal parasites
Origin Synthetic compound

1. Composition and Pharmacological Classification

The core chemical entity of Sirben is Mebendazole, a single-ingredient product recognized globally for its anti-parasitic properties. It is a synthetic compound derived from the Benzimidazole chemical structure, defining its specialized pharmacological group. Mebendazole is used as an agent with broad efficacy against multiple species of parasitic worms. This specialized classification as an anthelmintic drug means it is structurally and functionally distinct from anti-bacterial or anti-inflammatory medications. The compound's targeted action against these organisms supports its role in treating parasitic infestations.

2. Available Form, Patient Focus, and General Therapeutic Role

Sirben is typically supplied for oral administration in the form of a tablet or a liquid oral suspension. The availability of the oral suspension form is a differentiating factor, as it facilitates administration to patient groups who may struggle with swallowing tablets, such as young children. The general therapeutic role is to clear the body of these parasitic infestations. The drug's classification as an anthelmintic is consistent with its role in public health programs to control these infections. This means that Sirben serves an essential function in the elimination of the organisms responsible for causing helminthiasis in the general population, often being utilized for common infestations like pinworm or roundworm.

Regulatory References

  1. Mebendazole (US FDA Label)
  2. MedlinePlus
  3. Mebendazole Clinical Pharmacology (FDA Label)
  4. Mebendazole Tablet Form (FDA Label)

What side effects are possible with Sirben?

Possible Side Effects and Safety Information

The safety profile of Sirben, which contains the anthelmintic Mebendazole, is structured by classifying possible adverse reactions based on their frequency and the system they affect, as documented in official regulatory sources.

Frequency-Classified Adverse Reactions

The most frequently documented effects often involve the gastrointestinal system.

Classification Examples of Reactions
Common (reported in ge 1/100 to < 1/10 patients) Abdominal pain, Diarrhea, Flatulence
Uncommon (reported in ge 1/1,000 to < 1/100 patients) Nausea, Vomiting, Headache, Dizziness

Reactions classified as Rare include hepatic dysfunction, hepatitis, alopecia (hair loss), rash, urticaria, and neutropenia (a reduction in a specific white blood cell type).


Serious Adverse Reactions and Safety Constraints

The official labeling documents rare but serious adverse reactions, which primarily affect the Blood and Lymphatic System Disorders and the Skin and Subcutaneous Tissue Disorders. These include Agranulocytosis (severe drop in white blood cells), Hepatitis, Stevens-Johnson Syndrome (SJS), and Toxic Epidermal Necrolysis (TEN).

Safety notes explicitly state that rare, severe effects on the blood and liver are most frequently associated with high-dose or prolonged treatment regimens. A specific regulatory caution exists regarding co-administration: an increased risk of severe skin reactions (SJS/TEN) is documented when Mebendazole is used concurrently with Metronidazole.

Population-specific safety considerations are noted for children under 2 years of age, and the potential for hepatic reactions is a documented concern, particularly with higher dosing.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents define the manifestations of Sirben overdosage. In the event of accidental overdosage, the documented clinical manifestations primarily involve gastrointestinal disturbances, including abdominal cramps, nausea, vomiting, and diarrhoea.

Exposure to dosages substantially higher than recommended or for prolonged periods of time is associated with reports of more severe, systemic outcomes. These include hematological effects such as agranulocytosis and neutropenia, alongside reports of glomerulonephritis and hepatitis with reversible liver function disturbances. Due to these potential effects, monitoring of blood counts is noted as necessary when the product is used at higher-than-recommended doses.

Immediate medical attention is officially required if a person has taken too much of the medicine or if the product has been used for a longer duration than recommended. Urgent medical help must be sought for the presence of severe signs, such as convulsions or systemic distress. The label also contains a specific note regarding the risk of convulsions in infants below the age of 1 year.

It is officially documented that no specific antidote is known for Sirben overdosage. Management of overexposure is generally guided by symptomatic and supportive therapy. Officially described procedures may include the administration of activated charcoal and, where appropriate, measures like gastric lavage.

Therapeutic Uses of Sirben

Quick Facts About Sirben

  • Primary Use: Helps manage elevated blood pressure in adults.
  • Secondary Use: Indicated to support improved management of specific types of chronic fluid retention.
  • Therapeutic Goal: Works to maintain blood pressure within a target range and assist with fluid balance.

Sirben is a medication approved to address key areas of cardiovascular and renal health management. Its primary use is as a component of a therapeutic regimen intended to help manage high blood pressure (hypertension) in adult patients. Maintaining blood pressure at appropriate levels is a critical step in supporting long-term wellness.

Furthermore, Sirben is indicated to support improved management of certain forms of chronic fluid retention (edema) linked to specific conditions. The treatment aims to assist the body in achieving a more neutral fluid balance, which may help to alleviate physical discomfort and support organ function. Clinical evaluation suggests that Sirben may be an appropriate option for patients requiring a contribution toward the maintenance of both blood pressure control and fluid equilibrium.

Regulatory References

  1. NIH MedlinePlus guidance

Eligibility and Restrictions for Use

Eligibility and Contraindications

The eligibility profile for Sirben (Mebendazole) is strictly defined by official regulatory documentation, focusing on absolute exclusions and conditional use categories.

Sirben is contraindicated for any individual with a documented hypersensitivity to the medicine or its excipients. It must not be used in infants below the age of 1 year, a restriction based on the lack of established safety data and reports of convulsions in this age group.

Age-Related Eligibility

The medicine is approved for use in adults and children 2 years of age and older. Use in children between the ages of 1 and 2 years is deemed conditional and should only proceed if the potential clinical benefit justifies the potential risk, as safety is not fully established for this specific population.

Special Population Restrictions

Official labeling indicates that Sirben is not recommended for use during pregnancy, especially in the first trimester. Caution is advised for women who are breastfeeding.

Furthermore, special consideration is required for patients with pre-existing conditions. Regulatory authorities advise caution for individuals with impaired hepatic function (liver disease) or a history of bone marrow problems, particularly if the medicine is prescribed at higher doses or for prolonged treatment courses.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Sirben's official interaction profile, derived from regulatory documents, is structured around pharmacokinetic modifications and one mandatory prohibition.

Category Official Regulatory Information
Medicinal Product Categories Antiprotozoals, Anticonvulsants, H2-Receptor Antagonists.
Specific Interacting Medicines Metronidazole, Cimetidine, Carbamazepine, Phenytoin, Fosphenytoin.
Mechanistic Basis Pharmacokinetic (metabolic inhibition/induction), Pharmacokinetic (increased absorption).
Timing-Based Rules None documented.
Population-Specific Notes Hepatic Impairment: May lead to higher plasma concentrations.
Interaction Restrictions Strict avoidance with Metronidazole documented.

Official Interaction Statements:

  • Co-administration with Metronidazole carries the regulatory restriction of strict avoidance due to the documented risk of serious adverse skin reactions, including Stevens-Johnson syndrome/toxic epidermal necrolysis.
  • The co-administration of Cimetidine results in a pharmacokinetic interaction where Mebendazole's plasma concentration is increased through metabolic inhibition.
  • Co-administration with Carbamazepine, Phenytoin, or Fosphenytoin results in a pharmacokinetic interaction where Mebendazole's plasma concentrations are reduced due to increased metabolism.
  • The systemic absorption of the drug is officially documented to be increased when Mebendazole is administered with food, specifically a fatty meal.
  • Regulatory labeling notes that impaired function, such as hepatic impairment, may result in higher plasma concentrations of Mebendazole.

The overall interaction profile is defined by pharmacokinetic changes that alter systemic exposure and a single high-level regulatory restriction. The structure primarily classifies agents that are documented to significantly increase (Cimetidine) or decrease (select antiepileptics) the drug’s circulating levels, which must be considered against the observed increase in absorption when taken with a fatty meal.

Mechanism of Action

Selective Targeting of Parasite Microtubule Structure

Mebendazole exerts its action by acting as a specific inhibitor of helminthic beta-tubulin, the protein subunit essential for forming the parasite's microtubules. The drug binds with high affinity to the parasite's tubulin, blocking its polymerization and causing the progressive disassembly of necessary cytoskeletal structures, particularly within the absorptive intestinal cells (tegument).


Collapse of Nutrient Uptake and Energy Metabolism

The disruption of the microtubule structure in the parasite's digestive cells rapidly impairs its ability to absorb essential nutrients, primarily glucose. This blockade of nutrient uptake leads to the depletion of the worm's energy reserves (glycogen and ATP), initiating a severe energy deficit. This profound loss of energy and subsequent paralysis results in the parasite's inability to maintain its physiological function or attachment to host tissue, causing its eventual expulsion.

Dosage and Administration Information

How to use Sirben

Sirben, containing the active ingredient Mebendazole, is strictly administered via the oral route, typically supplied as a chewable tablet in 100 mg and 500 mg strengths. The administration regimen is highly defined and depends on the specific parasitic infection being managed. For the common pinworm infection, the standard regimen involves a single oral dose of 100 mg. For other infections, such as those caused by roundworm or hookworm, the standard protocol includes a 100 mg dose taken twice daily for three consecutive days, or alternatively, a 500 mg single dose.

Administration Details and Physical Handling

One of the key principles of administration is that Sirben may be taken with or without food, and no special dietary preparations, such as fasting or purging, are required. Specific handling instructions are determined by the tablet strength. The 500 mg chewable tablet must be chewed completely before swallowing; alternatively, it can be dispersed in 2–3 mL of drinking water for patients who have difficulty chewing. In contrast, the 100 mg tablet can be chewed, swallowed whole, or crushed and mixed with food.

Dosing Schedule and Duration

The standard dosing schedule established for adults is also applicable to pediatric patients two years of age and older. The total treatment course is either a single day or three consecutive days, depending on the regimen selected. If the infection is not cured following the initial course, a repeat course of treatment may be advised after a specific interval, such as two weeks.

Recent Clinical Evidence

Research evidence / Overview of studies for Sirben

This section provides an overview of the official research studies and regulatory evidence that have been conducted for Sirben (Mebendazole), focusing on its approved use for parasitic worm infections. This research provides context but not individual predictions, and findings describe group patterns, not personal outcomes.

Overview of Studies: Sirben for Intestinal Parasitic Infections

The foundation of the evidence for Sirben rests primarily on Randomized Controlled Trials (RCTs). These studies were used to evaluate the medicine's profile in large groups of people against specific parasitic infections. The findings from these trials, alongside larger Systematic Reviews and Meta-analyses that combine data from multiple studies, contribute to the body of evidence relied upon by regulatory bodies to understand the evidence landscape. The main focus of this research examined short-term parasitological clearance—meaning the measurement of whether parasite eggs were cleared from the feces after treatment.


Research Evidence for Ascariasis (Roundworm) and Enterobiasis (Pinworm)

The research base for Sirben concerning infections caused by roundworm (Ascariasis) and pinworm (Enterobiasis) is supported by a consistent volume of evidence in the scientific literature.

  • For Ascariasis, numerous short-term RCTs was studied for measuring how frequently the infection was cleared, specifically focusing on the Cure Rate (CR) and the Egg Reduction Rate (ERR). Findings describe patterns observed in the studies that show a high degree of reported consistency in the measurement of the clearance endpoint following standard treatment. Evidence provides insight into symptom patterns.

  • For Enterobiasis, the evidence is supported by clinical studies that have monitored the clearance of the pinworm infection. This research has a long history of clinical observation. Studies report how outcomes evolved in the observed populations, and the overall evidence is categorized as established, with the clearance endpoint being observed in a high percentage of treated individuals in trials.


Research Evidence for Trichuriasis (Whipworm) and Hookworm Infections

The evidence for infections caused by whipworm (Trichuriasis) and hookworm is based on RCTs, but the evidence level is generally categorized as more moderate or variable.

  • For Trichuriasis, research examined outcomes related to parasitological clearance, measuring the CR and ERR. While research highlights changes measured during the study period reported a measured reduction in parasite eggs (ERR), studies frequently report that the measured Cure Rate (CR) findings were mixed compared to the results for roundworm infection.

  • For Hookworm infections, studies monitored outcomes in children and adolescents. Research describes that the ERR was generally reliable. However, research describes that the measured Cure Rate (CR) findings when using only a single-dose regimen appear to be variable, and findings were mixed across different global regions.

Frequently Asked Questions (FAQ)

Common questions about Sirben (FAQ)


Q: What should I do if I think I am experiencing an allergic reaction to Sirben?

Official regulatory documents state that severe adverse reactions, including signs of an allergic reaction such as swelling of the face, lips, tongue, or throat, are considered serious adverse reactions that necessitate prompt contact with a healthcare provider. Rare but severe skin reactions, like Stevens-Johnson syndrome, are also documented as serious events.


Q: Are there any foods or drinks that should be avoided while taking Sirben?

The official product information indicates that the drug's systemic absorption is increased when it is administered with food, specifically a fatty meal. Regulatory documents do not list any specific foods or drinks that are required to be strictly avoided while taking this medicine.


Q: Can Sirben be used by people of all age groups (e.g., older adults or teenagers)?

The medicine is approved for use in adults and children two years of age and older, and the standard dosing schedule is established for these groups. Official regulatory information does not contain specific data on the effects or dosing relationship in geriatric (older) patients.


Q: How should Sirben be stored to keep it effective?

According to authoritative sources, the medicine should be stored in a closed container at controlled room temperature. It should be kept away from heat, moisture, and direct light, and it should not be frozen. It is officially recommended to store it out of the sight and reach of children.


Q: Is it safe to drive or operate machinery while taking Sirben?

The regulatory safety profile classifies dizziness and headache as uncommon adverse reactions to Sirben. Information on central nervous system effects suggests patients may need to observe their reaction to the medicine before driving or operating machinery.


Q: If Sirben is working, how will I know or what will I feel?

The medicine works by causing the parasite to lose energy and eventually be expelled from the body. Regulatory documents describe that in cases of massive infection, patients may experience transient symptoms like abdominal pain and diarrhea, which are reported in studies as associated with the clearance of the infection.


Q: How does the medicine Sirben get processed by the body (metabolism)?

According to the clinical pharmacology section of the official product information, the active ingredient is extensively processed, primarily by the liver. Only about 2% of the dose is typically found in the urine. The remainder of the drug and its primary metabolite are eliminated in the feces.


Q: What does the research evidence say about the long-term effectiveness of Sirben?

The official body of research primarily examines short-term parasitological clearance. However, regulatory information advises that periodic assessments of organ system functions, including blood (hematopoietic) and liver (hepatic) functions, are advisable when the drug is taken for prolonged therapy.


Q: Are there any required tests or monitoring while taking Sirben?

Regulatory documents advise that periodic assessment of organ system functions is advisable when the medicine is used for prolonged courses. This monitoring includes checking hematopoietic (blood) and hepatic (liver) functions.


Q: Can Sirben affect my ability to concentrate or focus?

The safety profile includes central nervous system adverse reactions such as dizziness and headache. Information on central nervous system effects suggests patients may need to be mindful of how these effects influence their day-to-day focus and activities.


Q: Does Sirben have a generic version available?

Yes. The active ingredient in Sirben is Mebendazole, which is the International Non-proprietary Name (INN) and the generic name for the drug.


Q: How long does the effect of a single dose of Sirben last in the body?

Regulatory documents describe the drug being extensively metabolized by the liver and primarily eliminated in the feces. Official patient information does not provide a specific duration of effect.


Q: What happens if I miss a scheduled dose of Sirben?

If a dose is missed, official guidance describes the process: it may be taken as soon as it is remembered. However, if it is almost time for the next scheduled dose, the missed dose should be skipped, and the regular schedule continued. Regulatory guidance states that double doses should be avoided.


Q: Is Sirben known to cause weight gain or weight loss?

Post-marketing surveillance indicates that potential side effects reported have included loss of appetite (anorexia) and weight loss. These reports reflect outcomes observed in patient groups.


Q: Can Sirben be taken by someone who has kidney problems?

Post-marketing experience with the drug includes rare reports of the kidney disorder glomerulonephritis. This has been reported particularly in cases involving higher doses or prolonged use.


Q: Does Sirben have a 'Black Box Warning' or a special safety alert?

Sirben (Mebendazole) is not documented to have a US FDA Black Box Warning. However, a specific regulatory caution exists regarding the drug's concurrent use with metronidazole, due to the documented risk of severe skin reactions.


Q: Is Sirben a controlled substance or addictive?

Official regulatory sources confirm that Sirben (Mebendazole) is not classified as a controlled substance. It is not listed under the US Controlled Substances Act.


Q: Do older adults need a lower dose of Sirben compared to younger adults?

The standard dosing schedule established for adults is also applicable to older patients. Official regulatory documents indicate that there is no specific information available on the relationship of age to the drug's effects in geriatric patients.


Q: Where can I find the official prescribing information (package insert) for Sirben?

Patients are advised by healthcare professionals to read the official US FDA-approved patient labeling, often referred to as Patient Information or the full Prescribing Information. This information can be found on official government sources such as DailyMed.

How should Sirben be stored and disposed of?

The storage and disposal instructions for Sirben (Bendamustine Hydrochloride) must adhere strictly to the guidelines for cytotoxic medicines.

Unopened Vials Storage

Unreconstituted vials must be stored at controlled room temperature, specifically below 25°C (77°F). The product should not be refrigerated or frozen. To protect the contents from light, the vial must be kept in its original carton until the time of use. As a mandatory safety requirement, Sirben must be stored out of the sight and reach of children.

Stability and Handling

Once the powder is reconstituted, the solution must be immediately diluted for infusion, with the transfer process completed within 30 minutes. The final infusion solution has a limited stability period: up to 24 hours when refrigerated (2 C to 8 C) or 3 hours at room temperature.

Disposal Requirements

Due to its cytotoxic nature, Sirben requires special waste handling. Unused medicine, waste materials, and partially used vials must be disposed of according to institutional and local regulations for hazardous medicinal products (antineoplastics). It must not be discarded into household waste or flushed down wastewater.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sirben found in:

A-Z Index: